Bolt Biotherapeutics Q2 EPS $(0.56) Misses $(0.48) Estimate, Sales $1.27M Beat $891.50K Estimate

Author: Benzinga Newsdesk | August 13, 2024 04:38pm
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 16.67 percent decrease over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $1.27 million which beat the analyst consensus estimate of $891.50 thousand by 43.02 percent. This is a 11.03 percent decrease over sales of $1.43 million the same period last year.

Posted In: BOLT